Endocare To Shed Non-Core Assets, Focus On Cryocare Indications
This article was originally published in The Gray Sheet
Executive Summary
Endocare is divesting "certain non-core" assets in order to concentrate resources on expanding adoption of its Cryocare prostate cancer platform and pursuit of additional applications